Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences (Nasdaq: PCRX) has announced that the U.S. District Court for the District of New Jersey has ruled its U.S. Patent No. 11,033,495 for EXPAREL invalid. Despite this setback, CEO Frank D. Lee expressed confidence in the company's intellectual property and believes eVenus is infringing on their patents. Pacira is considering legal options, including an appeal to the U.S. Court of Appeals for the Federal Court. The company maintains that the EXPAREL franchise is well-protected, citing three ongoing infringement suits and additional pending patents. Pacira BioSciences remains committed to its position as a leader in non-opioid pain management and regenerative health solutions.
Pacira BioSciences (PCRX) reported Q2 2024 financial results with total revenues of $178.0 million. Key highlights include:
- EXPAREL net product sales of $136.9 million
- ZILRETTA net product sales of $30.7 million
- iovera° net product sales of $5.7 million
- Net income of $18.9 million, or $0.41 per share (basic) and $0.39 per share (diluted)
- Adjusted EBITDA of $62.1 million
The company reiterated its full-year 2024 guidance, projecting total revenue of $680-705 million. Pacira also announced a $150 million share repurchase program and issued $287.5 million in convertible senior notes.
Pacira BioSciences, Inc. (NASDAQ:PCRX) has announced that it will release its second quarter 2024 financial results after U.S. markets close on Tuesday, July 30, 2024. The company will host a live conference call and webcast at 4:30 p.m. ET following the release. Interested participants can pre-register for the Q&A session via telephone, and all registrants will receive dial-in information and a PIN for call access. Additionally, a live audio webcast will be available through the 'Events' page on Pacira's investor website. For those unable to join the live call, a replay of the webcast will be accessible on the company's website for approximately two weeks after the event.
The Centers for Medicare and Medicaid Services (CMS) have proposed a new reimbursement rule for 2025, extending separate Medicare payments to non-opioid pain management drugs, including Pacira BioSciences' EXPAREL, in both ambulatory surgical centers (ASC) and hospital outpatient settings (HOPD). This proposal is part of the NOPAIN Act, included in the Consolidated Appropriations Act of 2023. If finalized, the rule will take effect on January 1, 2025. The reimbursement rates for non-opioid drugs will be set at average sales price (ASP) plus 6%. The proposed rate for EXPAREL is $1.41 per billing unit. EXPAREL is approved for local and regional analgesia for various surgical procedures and has been used in over 14 million patients in the U.S.
Pacira BioSciences (PCRX) will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on June 6, 2024, at 11:00 AM ET in New York.
The chat will be led by an analyst, and a live audio stream will be available on the company's website under the 'Events' section. A replay of the webcast will also be accessible for two weeks after the event.
Pacira BioSciences, Inc. announced the pricing of $250 million in convertible senior notes due 2029, with an option for additional notes. The net proceeds are estimated to be around $242 million, to be used for various purposes. The notes will bear interest at 2.125% per year and can be converted under certain conditions. Pacira also entered into capped call transactions to reduce potential dilution. The offering is made to qualified institutional buyers under Rule 144A.
Pacira BioSciences, Inc. announced a proposed offering of $250.0 million aggregate principal amount of convertible senior notes due 2029. The company intends to use the net proceeds for various purposes, including repurchasing existing notes, funding capped call transactions, and repurchasing shares of common stock. The offering is aimed at qualified institutional buyers and will involve privately negotiated capped call transactions to reduce potential dilution to common stock. Overall, the offering is part of Pacira's strategic financial planning to support its corporate goals.
Pacira BioSciences, Inc. (Nasdaq: PCRX) reported strong financial results for Q1 2024, with total revenues of $167.1 million. Net product sales included $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera°. The company also announced a $150 million share repurchase program, presented positive efficacy and safety data for PCRX-201, granted RMAT designation to PCRX-201, and secured three new EXPAREL patents. Financially, GAAP net income was $9.0 million, non-GAAP net income was $31.1 million, and adjusted EBITDA was $44.6 million. Pacira reaffirmed its 2024 financial guidance with a strong outlook for the year.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will be held in New York, with live audio accessible on the company's website. A replay will be available for two weeks.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will release its first quarter financial results on May 7, 2024, followed by a live conference call and webcast. Participants can dial 1-800-715-9871 (passcode 6363041) or 1-646-307-1963 for international callers. The webcast will be available on the Pacira website.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is the core focus of Pacira BioSciences Inc?
How does Pacira differentiate its products in the market?
What are the key commercial-stage products offered by Pacira?
What technology underpins Pacira's drug delivery system?
How does Pacira address the issue of opioid dependency?
What is PCRX-201 and what potential does it hold?
Which healthcare settings benefit from Pacira's therapies?
What role do reimbursement strategies play in Pacira's business model?
How does Pacira support clinical decision-making and patient care?
